Adjunct Collection of Additional Biorepository Data From Patients Enrolled in Diabetic Foot Consortium (DFC) Trials
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05092620 |
Recruitment Status :
Recruiting
First Posted : October 25, 2021
Last Update Posted : January 25, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Diabetic Foot Ulcer |
Study Type : | Observational |
Estimated Enrollment : | 500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Adjunct Collection of Additional Biorepository Data From Patients Enrolled in DFC Trials |
Actual Study Start Date : | May 1, 2021 |
Estimated Primary Completion Date : | December 31, 2023 |
Estimated Study Completion Date : | December 30, 2024 |

- Participants consenting [ Time Frame: Up to 2 years ]Proportion of participants consenting to participation in the biorepository from among DFC studies, by study and overall
- Biospecimens collected [ Time Frame: Up to 2 years ]Proportion of biospecimens collected, by type, from among those expected, by study and overall
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Provides written informed consent
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Age > 18 years
- Previous diagnosis of Type 1 or Type 2 diabetes or pre-diabetes per American Diabetes Association (ADA) guidelines
- Inclusion in a part of any planned or approved DFC protocol
Exclusion Criteria:
- An individual who meets exclusion criteria of the primary DFC protocol in which they are enrolled will also be excluded from participation in the biorepository program as well.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05092620
Contact: Katy Clark, MA | 7346156767 | DFC-DCC-PM@umich.edu | |
Contact: Tina Lucas, BS | DFC-DCC-PM@umich.edu |
United States, California | |
Stanford University | Recruiting |
Palo Alto, California, United States, 94305 | |
Contact: Shannon Meyer smeyer72@stanford.edu | |
Principal Investigator: Geoffrey Gurtner, MD | |
University of California, San Francisco | Recruiting |
San Francisco, California, United States, 94143 | |
Contact: Onorio Antonucci 415-353-4379 onorio.antonucci@ucsf.edu | |
Principal Investigator: Michael Conte, MD | |
United States, Florida | |
University of Miami | Recruiting |
Miami, Florida, United States, 33126 | |
Contact: Aliette Espinosa 305-689-3376 | |
Principal Investigator: Robert S Kirsner, MD, PhD | |
United States, Indiana | |
Indiana University | Recruiting |
Indianapolis, Indiana, United States, 46202 | |
Contact: Bryce Hockman 317-278-2715 | |
Principal Investigator: Chandan Chandan, PhD | |
United States, Michigan | |
University of Michigan | Recruiting |
Ann Arbor, Michigan, United States, 48109 | |
Contact: Aaron Burant 734-615-0552 aburant@med.umich.edu | |
Principal Investigator: Rodica Busui, MD, PhD |
Principal Investigator: | Brian Schmidt, DPM | University of Michigan | |
Study Chair: | Cathie Spino, ScD | University of Michigan |
Responsible Party: | Cathie Spino, ScD, Research Professor of Biostatistics, SABER Director, University of Michigan |
ClinicalTrials.gov Identifier: | NCT05092620 |
Other Study ID Numbers: |
HUM00193015 5U24DK122927-03 ( U.S. NIH Grant/Contract ) |
First Posted: | October 25, 2021 Key Record Dates |
Last Update Posted: | January 25, 2023 |
Last Verified: | January 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Diabetes, diabetic foot ulcer, DFU, wound, wound healing |
Diabetic Foot Foot Ulcer Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer |
Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases |